About This Desk

What this desk covers

Brand My Peptides reads the published literature on three compounds studied for weight management and metabolic regulation — semaglutide, tirzepatide and retatrutide — and reports what was measured, in whom, and at what point in a trial. It is a reference desk, not a clinic, not a pharmacy and not a shop.

The name deserves one sentence of its own, because it invites a reading that is wrong. Brand My Peptides brands nothing, labels nothing, formulates nothing and sells nothing. The name is a domain name, inherited rather than chosen as a description of a service, and there is no service. No supplier is named anywhere on this desk, no price is quoted, no vendor is compared and no sourcing question is entertained.

Why this desk leads with cessation

Every compound covered here has a famous number attached to it, and every one of those numbers was recorded at a moment when the participant was still receiving the drug. That is not a criticism of the trials; it is what the trials were designed to measure, and they measured it well. It becomes a problem only when a week-68 or week-72 figure is repeated as if it described a permanent property of a person rather than a state maintained by an ongoing intervention.

A separate and much smaller literature asks the other question. Randomised withdrawal designs and off-treatment extensions deliberately remove the compound and keep watching, and what they report is regain — proportional to the amount originally lost, with the cardiometabolic improvements moving back alongside the weight rather than staying banked.

That material is decision-relevant, it is systematically underrepresented in how these compounds are described publicly, and it is not difficult to summarise honestly. Organising a reference desk around it is the most useful thing this desk can do with three compounds that are otherwise very thoroughly covered elsewhere.

How an entry is built

Each compound entry follows the same order: a plain-English summary, what the compound is, how it works, what the research shows, what is reported and cautioned, and where the compound sits in the discontinuation record. That last section is this desk's addition to a standard structure.

Quantitative study claims carry a bracketed number pointing at the source list, and the same bracket always points at the same paper. The composed source list contains no direct withdrawal publication, so the stopping evidence is reported qualitatively and identified by study design rather than assigned a misleading citation from a different result. Retatrutide's missing withdrawal evidence is treated as a gap, not filled by analogy.

Anecdotal material appears only in clearly labelled blocks, is described as anecdotal and not clinical evidence at the point of use, and never carries a dose. It is included because it records texture that trial tables leave out, and for no stronger purpose than that.

Where the reporting stops

This desk does not give medical advice and does not address any reader as a patient. It names no dose, schedule, route or preparation for any person; where a quantity appears it is a description of what a published study administered, inside that study, and nothing more.

The cessation material carries an additional line that matters more here than anywhere else on the site. Describing what investigators measured when they withdrew a compound is not guidance about stopping one. This desk publishes no tapering scheme, no timing, no method and no view about whether anyone should start, continue or discontinue anything. Discontinuation appears on these pages strictly as an experimental condition that researchers created deliberately in order to measure it.

Semaglutide and tirzepatide are prescription medicines, and questions about them belong with a licensed prescriber. Retatrutide is investigational and available legitimately only inside a clinical trial. Where the literature is silent — as it currently is on what retatrutide does after it stops — this desk reports the silence rather than filling it in from a neighbouring compound.